双环[2.2.2]辛-5-烯-2-羧酸乙酯 | 42858-39-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 双环[2.2.2]辛-5-烯-2-羧酸乙酯
• 中文别名: 乙基双环[2,2,2]辛-5-烯-2-羧酸乙酯
• 英文名称: 5--bicyclo<2.2.2>octen-(2)
• 英文别名: Ethyl bicyclo[2.2.2]oct-5-ene-2-carboxylate
• CAS: 42858-39-9
• 化学式: C₁₁H₁₆O₂
• mdl: MFCD00180288
• 分子量: 180.247
• InChiKey: INGCFUDUPJPKMI-UHFFFAOYSA-N

物化性质

• 熔点：
  52-56 °C
• 沸点：
  98-100 °C(Press: 12 Torr)
• 密度：
  1.057±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.727
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2916209090

SDS

Name:	Ethyl bicyclo[2.2.2]oct-5-ene-2-carboxylate 95+% Material Safety Data Sheet
Synonym:
CAS:	42858-39-9

Section 1 - Chemical Product MSDS Name:Ethyl bicyclo[2.2.2]oct-5-ene-2-carboxylate 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
42858-39-9	Ethyl bicyclo[2.2.2]oct-5-ene-2-carbox	95+%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 42858-39-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H16O2
Molecular Weight: 180

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 42858-39-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl bicyclo[2.2.2]oct-5-ene-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 42858-39-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 42858-39-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 42858-39-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  双环[2.2.2]辛-5-烯-2-羧酸乙酯 在 吡啶 、 lithium aluminium tetrahydride 作用下， 生成 5-Methansulfonyloxymethyl-bicyclo<2.2.2>oct-2-en
  参考文献：
  名称：

  Tricyclo[4.4.0.03,8]decane to adamantane rearrangement

  摘要：

  DOI：

  10.1021/ja01020a028
• 作为产物：
  描述：

  原丙烯酸三乙酯 、 1,3-环己二烯 在 三氟甲磺酸三甲基硅酯 作用下， 以 二氯甲烷 为溶剂， 反应 0.3h， 以62%的产率得到双环[2.2.2]辛-5-烯-2-羧酸乙酯
  参考文献：
  名称：

  The low-temperature, ionic Diels-Alder addition of vinyl ortho esters to 1,3-dienes

  摘要：

  DOI：

  10.1021/jo00245a058

文献信息

• Organoselenium chemistry. Conversion of ketones to enones by selenoxide syn elimination
  作者：Hans J. Reich、James M. Renga、Ieva L. Reich

  DOI：10.1021/ja00852a019

  日期：1975.9

  of the selenoxide function. The many synthetic transformations originating from a,P-unsaturated carbonyl compounds have made their prep- aration a long standing important synthetic problem. The most straightforward method is the dehydrogenation of car- bonyl compounds. There are a number of methods for per- forming this the most important of which is the a-bromination-dehydrobromination method.' Orienta-

  已经研究了通过硒基化和硒氧化物消除将酮转化为烯酮的范围和限制。已经开发了几种制备α-苯基硒酮的方法。最有用的是使用 PhSeBr 对酮烯醇化物进行直接硒基化，以及烯醇乙酸酯与亲电子硒物质（如苯硒基三氟乙酸酯）的反应。描述了几种氧化剂（臭氧、过氧化氢、偏高碘酸钠）和反应条件，以优化将 a-苯基硒酮转化为烯酮的产率。该反应对于无环羰基化合物和叔硒化物非常普遍。当引入非常紧张的双键时，可能难以实现高产率，当 a-苯基硒酮是环状的并且有一个 a-氢时，或者当产物具有极强的反应性时。定性机理研究揭示了两种类型的副反应：（1）产生 a-二酮的类似普默勒的转化和（2）a-苯基硒基酮的烯醇或烯醇与苯硒酸歧化过程中形成的硒基化物质之间的反应. 已开发出使这些副反应最小化的反应条件。已经探索了苯硒酰氯作为硒酰化剂的效用。使用这种试剂可以实现酮到烯酮的一锅转化，收率令人满意，但由于氧化硒功能的敏感性，该过程容易
• [EN] METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION<br/>[FR] PROCÉDÉS DE PRÉPARATION D'INHIBITEURS DE LA RÉPLICATION DES VIRUS DE LA GRIPPE
  申请人：VERTEX PHARMA

  公开号：WO2015073481A1

  公开（公告）日：2015-05-21

  A method of preparing Compound (1) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (X): a pharmaceutically acceptable salt thereof with Compound (Y): in the presence of a palladium catalyst and a carbonate or phosphate base to form compound (Z): or a pharmaceutically acceptable salt thereof; and (b) deprotecting the Ts group of Compound (Z) to form Compound (1) or a pharmaceutically acceptable salt thereof.

  制备化合物（1）或其药用可接受盐的方法包括：（a）将化合物（X）：其药用可接受盐与化合物（Y）在钯催化剂和碳酸盐或磷酸盐碱的存在下反应，形成化合物（Z）或其药用可接受盐；（b）去保护化合物（Z）中的Ts基团，形成化合物（1）或其药用可接受盐。
• Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
  申请人：COCRYSTAL PHARMA, INC.

  公开号：US11014941B2

  公开（公告）日：2021-05-25

  Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient a safe and effective amount of a compound represented by any of Formulas I-III, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a safe and effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.

  抑制生物样本或患者体内流感病毒复制、减少生物样本或患者体内流感病毒数量以及治疗患者流感的方法，包括向所述生物样本或患者施用安全有效量的由式I-III中任一项代表的化合物或其药学上可接受的盐。药物组合物包括安全有效量的此类化合物或其药学上可接受的盐，以及药学上可接受的载体、佐剂或载体。
• Transition-metal peroxide reactions. Synthesis of .alpha.-hydroxycarbonyl compounds from enolates
  作者：E. Vedejs、D. A. Engler、J. E. Telschow

  DOI：10.1021/jo00396a002

  日期：1978.1
• New synthetic reactions. Sulfenylations and dehydrosulfenylations of esters and ketones
  作者：Barry M. Trost、Thomas N. Salzmann、Kunio Hiroi

  DOI：10.1021/ja00432a034

  日期：1976.8